A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
| Status: | Archived |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2009 |
| End Date: | November 2012 |
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521,
given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension
(CTEPH).
We found this trial at
14
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1351 Kimberly Rd
Bettendorf, Iowa 52722
Bettendorf, Iowa 52722
(563) 355-7733
Hematology Oncology Associates of the Quad Cities
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials